European urology
-
The degree of antitumour activity of enzalutamide following disease progression on docetaxel and abiraterone remains controversial. ⋯ Enzalutamide produces modest prostate-specific antigen (PSA) responses in patients progressing following chemotherapy and abiraterone. Despite a modest PSA response, survival may still be improved.